Predict your next investment

Metabolomic Diagnostics company logo
HEALTHCARE | Disease Diagnosis
metabolomicdiagnostics.com

See what CB Insights has to offer

Founded Year

2011

Stage

Convertible Note | Alive

Total Raised

$6.21M

About Metabolomic Diagnostics

Metabolomic Diagnostics is an early-stage medical diagnostics company dedicated to improving women's health. The company's focus is on developing screening tests which can assess, long before the appearance of clinical symptoms, a women's risk of developing compliance during pregnancy.

Metabolomic Diagnostics Headquarter Location

Hoffmann Park Inchera, Little Island

Cork, T45YX04,

Ireland

+353 21 4510263

Latest Metabolomic Diagnostics News

09:00 ET Constant Innovation Name of the Game in Preeclampsia Laboratory Testing Market, Says Fairfield Market Research

Sep 13, 2021

News provided by Share this article Share this article LONDON, Sept. 13, 2021 /PRNewswire/ -- Preeclampsia is the third most common cause of maternal mortality in the U.S. 10% of deaths are attributed to hypertension during pregnancy. As these deaths are largely preventable with early and effective diagnosis, there is an imperative to educate the general public about eclampsia and preeclampsia, boding well for stakeholders in the global preeclampsia laboratory testing market. Fairfield Market Research predicts that the global preeclampsia laboratory testing market was worth US$1242.9 in 2020 and should grow to US$2,021.1 Mn by 2025, witnessing a CAGR of 10.2% for the period. Get a Sample Copy of Preeclampsia Laboratory Testing Market: https://www.fairfieldmarketresearch.com/report/preeclampsia-laboratory-testing-market/request-sample   Rapid Launches and Market Flux Characterise Preeclampsia Laboratory Testing Market Research and development collaborations coupled with relentless product launches characterise the preeclampsia laboratory testing market. In 2019, DiabetOmics, an American diagnostics company launched Lumella - a rapid point-of-care test that estimated Glycosylated Fibronectin (GlyFN) – a protein biomarker found in pregnant women prone to developing preeclampsia. In mid-2020, Igenomix and Ferring Pharmaceuticals announced their partnership to develop therapeutic strategies and improve diagnostic techniques for treating preeclampsia. Need to Treat Preeclampsia in Time Aids Growth in Preeclampsia Laboratory Testing Market There has been a noticeable boom in preeclampsia laboratory tests in emerging economies. As per data from the Ethiopian National Emergency Obstetric and Newborn Care, nearly 10% of both direct and indirect maternal mortality can be attributed to preeclampsia. Similar figures are reported in the world's second most populous country – India. The developed world is not spared from the burden of preeclampsia either. According to the Preeclampsia Foundation, preeclampsia short term medical costs in the U.S. alone are US $2.1 billion. While the average cost a year after delivery is typically US$ 1.03 billion, this rises to US$ 1.15 billion for infants born to mothers afflicted with preeclampsia. Thus, the necessity to treat preeclampsia-related complications directly benefits the preeclampsia laboratory testing market. Accuracy Helps Blood Tests Secure Pole Position in Preeclampsia Laboratory Testing Market Blood tests hold a commanding position in the test type category of the preeclampsia laboratory testing market and are on track to remain number one during the assessment period. Blood tests are far more accurate than urine tests, explaining their preference amongst patients. There have been several novel biomarkers that have been unveiled in the preeclampsia laboratory testing market recently and companies would do well to target this dynamic segment of the preeclampsia laboratory testing market. Do You Have Any Query Or Specific Requirement? Request Customization of Report:  https://www.fairfieldmarketresearch.com/report/preeclampsia-laboratory-testing-market/request-customization   Federal Support and Advocacy Groups Makes U.S Critical from Bottom Line Perspective North America dominates the global preeclampsia laboratory testing market in revenue terms, due to numerous government initiatives along with patient advocacy groups meant to offer a better diagnostics regimen. The North America preeclampsia laboratory testing market was worth US$ 465.6 million in 2020 and should witness double-digit growth until 2025. In 2019, the Food and Drug Association (FDA) authorized an advanced prenatal therapeutics (APT) breakthrough device designation for Targeted Apheresis Column for Preeclampsia (TAC-PE). APT's device specifically removes disease-causing factors from the mother's blood. Nevertheless, the densely populated APAC region has immense potential and should not be ignored by companies actively involved in the preeclampsia laboratory testing market. China and India have the unfortunate distinction of having particularly high rates of preeclampsia. For e.g. – The Pregnancy Hypertension journal states that the occurrence of preeclampsia in China is 9.5% in 2019, demonstrating how essential pre-emptive care is. Key Players in the Preeclampsia Laboratory Testing Market Companies profiled in the preeclampsia laboratory testing market are SERA Prognostics, Bayer AG, Siemens Healthineers AG, Metabolomic Diagnostics Ltd., DiabetOmics Inc., DRG INSTRUMENTS GMBH, Progenity Inc. SERA Prognostics, Bayer AG, Siemens Healthineers AG, Metabolomic Diagnostics Ltd., DiabetOmics Inc., DRG INSTRUMENTS GMBH, and Progenity, Inc. Browse Our Latest Trending Reports:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Metabolomic Diagnostics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Metabolomic Diagnostics is included in 5 Expert Collections, including Women's Health & Wellness.

W

Women's Health & Wellness

957 items

Startups focused on providing products and services catering to women's health and wellbeing.

M

Medical Devices

7,867 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health Monitoring & Diagnostics

2,390 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

D

Diabetes

1,750 items

O

Omics

1,029 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Metabolomic Diagnostics Patents

Metabolomic Diagnostics has filed 1 patent.

The 3 most popular patent topics include:

  • Diabetes
  • Midwifery
  • Neonatology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/11/2019

Diabetes, Midwifery, Obstetrics, Neonatology, Women's health

Application

Application Date

2/11/2019

Grant Date

Title

Related Topics

Diabetes, Midwifery, Obstetrics, Neonatology, Women's health

Status

Application

Metabolomic Diagnostics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Metabolomic Diagnostics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.